Reviewing OptimizeRx (NASDAQ:OPRX) and Pheton (NASDAQ:PTHL)

Pheton (NASDAQ:PTHL) and OptimizeRx (NASDAQ:OPRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Analyst Recommendations

This is a summary of current recommendations and price targets for Pheton and OptimizeRx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
OptimizeRx	1	2	6	0	2.56

OptimizeRx has a consensus price target of $11.43, indicating a potential upside of 43.76%. Given OptimizeRx’s stronger consensus rating and higher probable upside, analysts clearly believe OptimizeRx is more favorable than Pheton.

Volatility and Risk

Pheton has a beta of 5.4, suggesting that its share price is 440% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500.

Institutional & Insider Ownership

76.5% of OptimizeRx shares are owned by institutional investors. 7.5% of OptimizeRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pheton and OptimizeRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
OptimizeRx	4.66%	9.44%	7.11%

Valuation and Earnings

This table compares Pheton and OptimizeRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305,215.00	6.47	-$660,000.00	N/A	N/A
OptimizeRx	$109.43 million	1.37	$5.13 million	$0.23	34.57

OptimizeRx has higher revenue and earnings than Pheton.

Summary

OptimizeRx beats Pheton on 10 of the 12 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.